Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher

Sponsored:

Monday, November 11, 2024

This late-stage clinical trial company focuses on preventing inflammation and acute organ injury. It is developing a platform of new drugs to prevent inflammation in the kidneys, liver and lungs via the dipeptidase-1 (DPEP1) pathway, addressing common injuries and diseases where organ inflammation remains an unmet need. And now, they are looking at a major breakthrough in treating common injuries and diseases where organ inflammation affects millions of patients globally annually with an LSALT peptide. 

Arch Biopartners Inc. (TSX Venture: ARCH) (OTCQB: ACHFF) announced in a press release today that patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). Acute kidney injury (AKI) is a common complication, with an increased risk in patients undergoing coronary artery bypass grafting (CABG) and other on-pump cardiac surgeries. The reported prevalence of CS-AKI is up to 30 percent, and it is independently associated with higher morbidity and mortality rates.

The CS-AKI Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled study of LSALT peptides with a recruitment target of 240 patients. The trial’s primary objective is to evaluate the percentage of subjects with acute kidney injury (AKI) within seven days following on-pump (heart-lung machine) cardiac surgery, as defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria.

Sponsored: